Enrique Grande: Poor Outcomes for Basal/Squamous and Mixed Bladder Cancers in the VESPER Trial
Enrique Grande shared the following on LinkedIn:
“Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.”
Authors: C.S. Groeneveld, C. Pfister, S. Culine, V. Harter, C. Krucker, J. Fontugne, V. Dixon, N. Sirab, I. Bernard-Pierrot, A. de Reyniès, F. Radvanyi, Y. Allory, VESPER trial investigators.
Source: Enrique Grande/LinkedIn
Enrique Grande, MD, PhD, MSc, is an Associate Professor at Francisco de Vitoria University. He is also an Adjunct Professor at the GU Medical Oncology Department and the Head of Oncology at MD Anderson Cancer Center. Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit. He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE). Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023